Through you, Mr. Chair, thank you, Mr. Julian, for allowing me to continue because, for the story that you told about Amber, we could go into every single riding in every single constituency across this country and, unfortunately, we would have a similar story.
My colleague Mr. Williams talked about the calls that we are getting to our 1-800 line. Very similarly to what Ms. Eagan was saying, we receive calls from individuals who have no coverage, like Amber, and who are spending, in her case, like you said, $1,000 a month just to get the care that she needs, and that's devices and medications. We also have individuals who are living with either type 1 or type 2 diabetes who have private insurance. It's at, let's say the 80% level. However, the 20% level is still difficult for them to meet at the end of the month, so they're rationing, as my colleague Mr. Williams also outlined in his opening statement.
That's why we continue to talk about our three recommendations, because those are the key points that we think.... The debate about what is universal, first-dollar, single-payer—as Mr. Powlowski talked about—hasn't been defined yet. We keep talking about the under-insured and uninsured. We have an opportunity here—“we” being everyone at this table, diabetes organizations, contraception organizations—to actually look at making sure we can fill those gaps, and if that isn't the right term, let's figure out what the right term is to make sure that the choice and the opportunity to continue to move forward is still there while we're figuring out how we make this work in the negotiations that happen with the provinces.
We talk about that fulsome and robust consultation that we would like to see with persons with lived experience, like me, like Mr. Kitchen and everyone else across the country. Let's look at the comprehensiveness. In the bill it talks about section 4 and looks at how the Canada Health Act can be included, and some of our legal interpretation talks about making sure that we look at the comprehensiveness of that choice and then, of course, what we're calling “do no harm”. We need to ensure that individuals who have wraparound care still have it, but let's not forget about Amber or about anybody else we could talk to, in any one of these constituencies across the country, who needs that support.